Eisai sues FDA over shortened marketing period for 2 drugs

Eisai filed a lawsuit to force the FDA to extend the drugmaker's marketing exclusivity period on diet drug Belviq and epilepsy drug Fycompa after listing delays by the U.S. Drug Enforcement Agency delayed the drugs' launch, thus shortening the marketing exclusivity period.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of Massachusetts
Boston, MA
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide